The FDA’s upcoming June meeting plans to jab at a lineup of vaccines—COVID-19, RSV, flu, and even anthrax—but somehow skipped ...

The panel, known as the Advisory Committee on Immunization Practice, is due to meet on June 25 and 26. It will vote on the ...

A few of the new members Health Secretary Robert F. Kennedy Jr. appointed to the federal panel have promoted misinformation ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and ...

The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 ...

Merck & Co., Inc. (NYSE:MRK) is one of the best wide moat stocks to buy now. On June 9, Merck’s preventative antibody shot ...

The FDA has approved Merck’s Enflonasia, a monoclonal antibody designed to prevent respiratory syncytial virus lower respiratory tract disease in newborns and infants. The approval is based on data ...

On the 9th (local time), Merck announced that its RSV preventive antibody injection for infants, Enflonsia, received product approval from the U.S. Food and Drug Administration (FDA).

Merck intends to make the drug available in the U.S. before the start of the 2025-2026 RSV season, with ordering beginning in July. While ENFLONSIA has been approved for use, it is not recommended for ...